

August 14, 2026

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroze Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
--	---

Dear Sir/Madam,

Sub: Unit I of Eugia Pharma Specialities Ltd. receives Warning Letter from US FDA – Reg.,
Ref : Our letters dated May 24, 2026 and February 27, 2026

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that:

This is further to our communication dated May 24, 2026, about Unit-I, a Formulation manufacturing facility, of Eugia Pharma Specialities Ltd., a wholly owned subsidiary of the Company, receiving Official Action Indicated (OAI) status by the US FDA. Subsequent to OAI, the unit has received a Warning Letter.

There is no impact on the existing supplies to the US markets. Unit I of Eugia Pharma Specialities Ltd., is contributing to ~2% to Company's overall group revenue.

The Company remains committed to working closely with the US FDA and continues to enhance its compliance on an ongoing basis.

We will keep the stock exchanges informed about further developments.

Please take the above information on record.

Thanking you,

Yours faithfully,
For **AUROBINDO PHARMA LIMITED**

B. Adi Reddy
Company Secretary

AUROBINDO PHARMA LIMITED

www.aurobindo.com

(CIN : L24239TG1986PLC015190)

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithriviham, Ameerpet, Hyderabad - 500 038, Telangana., India. Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com